Magro Fernando, Portela Francisco, Lago Paula, Chagas Cristina, Moreira Francisco, Pereira Fábio, Rodrigues Bernardo, Pedrosa Hugo, Correia Luis
Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal.
IBD Portuguese Group (GEDII), Porto, Portugal.
GE Port J Gastroenterol. 2022 Jun 15;30(4):283-292. doi: 10.1159/000525206. eCollection 2023 Aug.
Inflammatory bowel diseases' (IBD) increasing incidence and prevalence place a heavy health and economic burden on society.
This study assesses the burden and cost of IBD in Portugal to support the definition of health policies, resource allocation, and patient care.
The burden of disease was expressed using disability-adjusted life years (DALY). Costs were estimated considering the societal perspective, using a prevalence-based model and prices established by law. An expert panel composed of 5 expert Portuguese gastroenterologists and a patient-reported study were conducted to support the cost analysis and fill in information gaps.
In Portugal, with a prevalence of 24,069 IBD patients and an incidence of 15/100,000, the burden of disease was estimated at 6,067 DALYs: 507 resulting from premature deaths and 5,560 from disability. Total cost was estimated at EUR 146 million per year, with direct costs representing 59%. Average yearly cost per IBD patient is EUR 6,075, where 60% is related to Crohn's disease and 40% to ulcerative colitis (UC).
This study estimates the annual health burden and cost of IBD in Portugal, thus generating information with the intent to raise awareness of the need to advance health policies as well as better clinical and economic decisions in this pathology.
炎症性肠病(IBD)发病率和患病率的不断上升给社会带来了沉重的健康和经济负担。
本研究评估葡萄牙IBD的负担和成本,以支持卫生政策的制定、资源分配和患者护理。
使用伤残调整生命年(DALY)来表示疾病负担。从社会角度出发,采用基于患病率的模型和法定价格估算成本。由5名葡萄牙胃肠病学专家组成的专家小组和一项患者报告研究,以支持成本分析并填补信息空白。
在葡萄牙,IBD患者患病率为24,069例,发病率为15/100,000,疾病负担估计为6,067个DALY:507个由过早死亡导致,5,560个由残疾导致。每年总成本估计为1.46亿欧元,直接成本占59%。每名IBD患者的平均年度成本为6,075欧元,其中60%与克罗恩病相关,40%与溃疡性结肠炎(UC)相关。
本研究估计了葡萄牙IBD的年度健康负担和成本,从而产生相关信息,旨在提高人们对推进卫生政策以及针对该疾病做出更好的临床和经济决策必要性的认识。